Lead Optimization and Preclinical Drug Candidate Validation

LIDE specializes in preclinical studies, offering traditional R&D in-vitro and in-vivo services but recommend a different R&D roadmap for potential drug candidates:

  1. Using conditionally reprogrammed (CR) cells instead of genetically engineered cell lines for in-vitro studies
  2. Testing or validating indications by leveraging our Functional Diagnosis MiniPDX before in-vivo validation
  3. Jumping straight to PDX studies after Functional Diagnosis
  4. Biomarker identification for patient stratification to inform recruitment strategy

Our biobank offers rare cancer types, hard-to-find genetic mutations and drug resistant models, with 1600+ PDX models and many high profile expression phenotypes.

Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform

Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform